Enliven Therapeutics, Inc. Common Stock

ELVNNASDAQ • USD
47.26 USD
↘ 0.36 (0.76%)🟢LIVE (AS OF 01:32 PM EST)
🟢Market: OPEN

ELVN is currently priced at $47.26. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, ELVN trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 16, 2026.

Open?$47.61
High?$48.05
Low?$43.37
Prev. Close?$47.62
Volume?369.6K
Avg. Volume?1.5M
VWAP?$46.85
Rel. Volume?0.25x
Bid / Ask
Bid?$40.43 × 100
Ask?$47.10 × 100
Spread?$6.67
Midpoint?$43.77
Valuation & Ratios
Market Cap?3.5B
Shares Out?73.6M
Float?60.8M
Float %?83.0%
P/E Ratio?N/A
P/B Ratio?4.00
EPS?-$1.54
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Employees
65
Market Cap
3.6B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2023-02-24
Address
205 PARK ROAD
BURLINGAME, CA 94010
Phone: 650-547-5814
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
26
Piotroski F-Score?0/9Weak
Altman Z-Score?103.70Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?16.92%High
Short Interest?10.3M
Days to Cover?5.7
Free Float60.8M
Avg Daily Volume1.8M
Settlement Date2026-10-30
Financial Health
Current Ratio?45.95Strong
Quick Ratio?45.95Strong
Cash Ratio?7.79Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
44
4.00FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-24.8CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
9
-12.9%WEAK▾
ROA?
S&P
3
-12.7%WEAK▾
Cash Flow & Enterprise
FCF?$-66408000
Enterprise Value?$3.4B
Fundamentals ratios updated end of day